Quinlivan Katherine M, Howard Isabella V, Southan Franciska, Bayer Rachel L, Torres Kimberly L, Serhan Charles N, Panigrahy Dipak
Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States.
Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States.
Prostaglandins Other Lipid Mediat. 2025 Jun;178:106944. doi: 10.1016/j.prostaglandins.2024.106944. Epub 2024 Dec 24.
Unresolved chronic inflammation, a hallmark of cancer, promotes tumor growth and metastasis in various cancer types. In contrast to blocking inflammation, stimulation of resolution of inflammation is an entirely novel approach to "resolve" inflammation. Resolution of inflammation mechanisms in cancer includes clearance of tumor debris, counter-regulation of pro-inflammatory eicosanoids and cytokines, and suppression of leukocyte infiltration. Conventional cytotoxic chemotherapy, radiation, anti-angiogenic therapy, and immune checkpoint inhibitors directly or indirectly can lead to the generation of pro-tumorigenic cellular debris. Over the past two decades, a potential paradigm shift has emerged in the inflammation field with the discovery of specialized pro-resolving mediators (SPMs), including resolvins, lipoxins, maresins, and protectins. SPMs are structurally distinct families of mediators grouped together by their pro-resolving "debris-clearing" functions. "Pro-resolving" therapies are in clinical development for various inflammation-driven diseases, including cancer. SPMs, as novel cancer therapeutics, have tremendous potential to enhance current cancer therapy. The mechanisms of SPMs as anti-cancer therapeutics are under active investigation by various laboratories worldwide. Here, we explore the current appreciation of the SPMs as innovative potential treatments designed to harness the unique anti-cancer activity of SPMs.
未解决的慢性炎症是癌症的一个标志，它促进多种癌症类型的肿瘤生长和转移。与阻断炎症不同，刺激炎症消退是一种全新的“解决”炎症的方法。癌症中炎症消退机制包括清除肿瘤碎片、对促炎类二十烷酸和细胞因子进行反调节以及抑制白细胞浸润。传统的细胞毒性化疗、放疗、抗血管生成疗法和免疫检查点抑制剂直接或间接可导致促肿瘤细胞碎片的产生。在过去二十年中，随着包括消退素、脂氧素、maresin和保护素在内的特殊促消退介质（SPM）的发现，炎症领域出现了潜在的范式转变。SPM是结构不同的介质家族，因其促消退的“碎片清除”功能而被归为一类。“促消退”疗法正在针对包括癌症在内的各种炎症驱动疾病进行临床开发。SPM作为新型癌症治疗药物，具有增强当前癌症治疗效果的巨大潜力。世界各地的多个实验室正在积极研究SPM作为抗癌治疗药物的机制。在此，我们探讨当前对SPM作为旨在利用其独特抗癌活性的创新潜在治疗方法的认识。
